Global Idiopathic Pulmonary Fibrosis (IPF) Market - 2021-2028
発行: DataM Intelligence
ページ情報: 英文 180 Pages
The global idiopathic pulmonary fibrosis (IPF) market size was valued at US$ YY million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).
Idiopathic pulmonary fibrosis (IPF) is a potentially fatal lung disease. The fibrosis that develops in the lungs is thought to result from abnormal tissue repair after tissue damage. This atypical repair response is most likely the result of a combination of genetic and environmental factors.
The factors influencing idiopathic pulmonary fibrosis (IPF) market growth are increasing clinical trials of drugs for pulmonary disorders.
Increasing clinical trials of drugs for pulmonary disorders is expected to drive the market growth
The FDA has currently approved two drugs to treat idiopathic pulmonary fibrosis (IPF), the most common form of PF. Nintedanib (Ofev) and pirfenidone (Esbriet) are two examples. These medications are known as anti-fibrotic agents because clinical trials have shown that they slow the rate of fibrosis or scarring in the lungs. These medications are approved for patients suffering from mild, moderate, or severe IPF. While neither medication is preferred over the other, one may be more effective for you. Over 600 drugs are known to cause pulmonary toxicity, and illicit drugs are well-known to cause pulmonary toxicity.
On March 9th, 2020, The FDA approved Ofev (nintedanib) oral capsules for the treatment of patients with chronic fibrosing (scarring) Nintedanibs (ILD) with a progressive phenotype (trait). It is the first FDA-approved treatment for this group of progressive fibrosing lung diseases.
Lack of diagnosis and side effects of drugs are expected to hamper the market growth
Many medications, including herbal products, have been linked to pulmonary adverse events. However, the definitive diagnosis of idiopathic pulmonary fibrosis (IPF) remains difficult due to the non-specific clinical presentation and the lack of confirmatory diagnostic tests. Pirfenidone tablets or capsules are typically taken three times daily with food by people with IPF. More than 10% of people experience nausea, acid reflux (heartburn), vomiting, decreased appetite, weight loss, headache, dizziness, fatigue, and skin problems such as a "photosensitivity" rash that develops in response to sun exposure. Overall, pirfenidone side effects are common, but they are usually manageable enough that most patients can continue treatment. These medications may have interactions with other medications or supplements.
Pulmonary fibrosis can develop due to chronic inflammation or as a result of a primary, genetically influenced, age-related fibroproliferative process, as in idiopathic pulmonary fibrosis (IPF). Pulmonary fibrosis is a well-known complication of acute respiratory distress syndrome. A common clinical condition is drug-induced acute respiratory distress syndrome (ARDS). However, most follow-up studies have shown that persistent radiographic abnormalities after ARDS are of little clinical significance and have become less common in the era of protective lung ventilation. According to studies, approximately 40% of COVID-19 patients develop ARDS, with 20% of ARDS cases being severe. The mortality rate of COVID-19 ICU patients is 40%, and that of those who received IMV is 59%; the mortality rate of COVID-19-associated ARDS is 45%, and the incidence of ARDS among COVID-19 non-survivors is 90%. Hence, COVID-19 highly impacted the global idiopathic pulmonary fibrosis (IPF) market.
Drugs segment held the largest market share in the global idiopathic pulmonary fibrosis (IPF) market
As the number of therapeutic drugs available grows, the list of drugs is linked to severe pulmonary disease. Many drugs have been linked to various types of pulmonary complications. Nintedanib is a drug used to treat idiopathic pulmonary fibrosis (IPF, scarring of the lungs with an unknown cause). It is also used to treat some chronic fibrosing Nintedanibs (ILD, a persistent disease with increased scarring of the lungs). Nintedanib is also used to slow the progression of deterioration in lung function in people with systemic sclerosis associated Nintedanib. It is a kinase inhibitor, which is a type of drug. It works by preventing the action of fibrosis-causing enzymes.
On March 9, 2020, Boehringer Ingelheim's Ofev (nintedanib) was approved by the US Food and Drug Administration (FDA) as the first treatment for people with chronic fibrosing Nintedanibs (ILDs) with a progressive phenotype. Ofev is currently approved to treat idiopathic pulmonary fibrosis (IPF).
North America region accounted for the largest market share in the global idiopathic pulmonary fibrosis (IPF) market
The increasing pulmonary disorders in this region are expected to increase the market growth. In the United States, approximately 100,000 people are affected with idiopathic pulmonary fibrosis (IPF), with 30,000 to 40,000 new cases diagnosed each year. Hence, this region is estimated to dominate the global idiopathic pulmonary fibrosis (IPF) market.
On September 6th, 2019, Ofev (nintedanib) capsules were approved by the U.S Food and Drug Administration to slow the rate of decline in pulmonary function with systemic sclerosis or scleroderma, also known as SSc-ILD. It is the first FDA-approved therapy for this rare lung disease.
The global idiopathic pulmonary fibrosis (IPF) market is moderately competitive with company mergers, acquisitions, and new drug approvals for treatment.
Some of the major key players in this market are Galapagos nv., Boehringer Ingelheim GmbH, FIBROGEN, INC., MEDICINOVA, INC., Liminal BioSciences, f. Hoffmann-la Roche ltd, Bristol-Myers Squibb Company and Theravance biopharma Mylan inc.
Boehringer Ingelheim GmbH
Overview: Boehringer Ingelheim is the world's largest pharmaceutical company and the largest private company. It is the world's largest pharmaceutical company, as well as the largest private company. It was founded in 1885 by Albert Boehringer in Germany.
Product Portfolio: The company manufactures Ofev, which is used to treat patients with idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated Nintedanib (SSc-ILD), and other chronic fibrosing Nintedanibs with a progressive phenotype in some countries.
Key Development: On March 9, 2020, The FDA approved Ofev (nintedanib) as the first treatment for chronic fibrosing Nintedanibs (ILDs) with a progressive phenotype.
Visualize the composition of the global idiopathic pulmonary fibrosis (IPF) market segmentation by treatment and end-user highlighting the key commercial assets and players.
Identify commercial opportunities in global idiopathic pulmonary fibrosis (IPF) market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of global idiopathic pulmonary fibrosis (IPF) market- level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global idiopathic pulmonary fibrosis (IPF) market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Global Idiopathic Pulmonary Fibrosis (IPF) Market- By Treatment
Global Idiopathic Pulmonary Fibrosis (IPF) Market- By End-User
Global Idiopathic Pulmonary Fibrosis (IPF) Market- By Region
Middle East and Africa